BiotechTube

ONO-7746

Phase 1Terminated
0 watching 0 views this weekπŸ’€ Quiet
33
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chemotherapy-Induced Thrombocytopenia

Conditions

Chemotherapy-Induced Thrombocytopenia

Trial Timeline

May 1, 2011 β†’ β€”

NCT ID
NCT01345214

About ONO-7746

ONO-7746 is a phase 1 stage product being developed by Ono Pharmaceutical for Chemotherapy-Induced Thrombocytopenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01345214. Target conditions include Chemotherapy-Induced Thrombocytopenia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01345214Phase 1Terminated

Competing Products

20 competing products in Chemotherapy-Induced Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
GranisetronKyowa KirinPhase 3
77
ONO-2910 + PlaceboOno PharmaceuticalPhase 2
52
PROCRIT 40,000 IU QW + PlaceboJohnson & JohnsonPhase 2
52
Hetrombopag Olamine + Hetrombopag Olamine οΌ›Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
52
Hetrombopag + Hetrombopag plus Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + Matching placeboJiangsu Hengrui MedicinePhase 3
77
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
Fosaprepitant dimeglumine + Fosaprepitant Placebo + Dexamethasone + Ondansetron + Dexamethasone Placebo + Ondansetron Placebo + Rescue TherapyMerckPhase 3
77
FosaprepitantMerckPhase 2
52
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonistMerckPhase 3
77
Fosaprepitant + Dexamethasone + 5HT3MerckPhase 2
52
aprepitant + Comparator: Placebo to aprepitant + dexamethasone + granisetron + dexamethasoneMerckPhase 3
77
aprepitant + Comparator: ondansetron + Comparator: dexamethasone + Comparator: fosaprepitant dimeglumine + Comparator; Placebo (unspecified) + Comparator; Placebo (unspecified)MerckPhase 3
77
EMENDMerckPre-clinical
23
Fosaprepitant Dimeglumine + 5-HT3 antagonist + DexamethasoneMerckApproved
85
ondansetron clinical trial formulation + ondansetron marketed formulationMerckPhase 1
33
Aprepitant + Palonosetron + DexamethasoneMerckPhase 2
52
Fosaprepitant 150 mg + Aprepitant 165 mg + Aprepitant 250 mg + Dexamethasone (12-8-16-16 mg) + Dexamethasone (12-8-8-16 mg) + Ondansetron + MK0999MerckPhase 1
33

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77